Evidence map›Paper›PMID 32756371›Full record

ArticleInternational journal of environmental research and public health2020

BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study.

Mitsuyoshi Urashima, Katharina Otani, Yasutaka Hasegawa, Taisuke Akutsu

Registry-linked trialAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04659941 (Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers), which is not on this map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04659941 phase2unknown statusnot on this map

Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers

TypeinterventionalSponsorUniversidade Federal do Rio de JaneiroRan2020 to 2024Enrolled752ConditionsCOVID 19 VaccineArmsBCG vaccine, 0.9% sodium chloride (NaCl) saline solution
3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Pathogenesis of SARS-CoV-2 andFrontiers in immunology · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mitsuyoshi UrashimaDivision of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.ORCID 0000-0002-7395-5831
Katharina OtaniDivision of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.ORCID 0000-0002-2322-3405
Yasutaka HasegawaDivision of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
Taisuke AkutsuDivision of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ecological studies have suggested fewer COVID-19 morbidities and mortalities in Bacillus Calmette-Guérin (BCG)-vaccinated countries than BCG-non-vaccinated countries. However, these studies obtained data during the early phase of the pandemic and did not adjust for potential confounders, including PCR-test numbers per population (PCR-tests). Currently-more than four months after declaration of the pandemic-the BCG-hypothesis needs reexamining. An ecological study was conducted by obtaining data of 61 factors in 173 countries, including BCG vaccine coverage (%), using morbidity and mortality as outcomes, obtained from open resources. 'Urban population (%)' and 'insufficient physical activity (%)' in each country was positively associated with morbidity, but not mortality, after adjustment for PCR-tests. On the other hand, recent BCG vaccine coverage (%) was negatively associated with mortality, but not morbidity, even with adjustment for percentage of the population ≥ 60 years of age, morbidity, PCR-tests and other factors. The results of this study generated a hypothesis that a national BCG vaccination program seems to be associated with reduced mortality of COVID-19, although this needs to be further examined and proved by randomized clinical trials.

Indexed as

BCG VaccineBetacoronavirusCoronavirus InfectionsCOVID-19HumansMiddle AgedPandemicsPneumonia, ViralResearch DesignSARS-CoV-2VaccinationBCG VaccineBacillus Calmette–GuérinBCGcoronavirus disease 2019COVID-19ecological studymorbiditymortalitySARS-CoV-2urbanizationvaccination

Identifiers

PMID32756371
PMCPMC7432030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.